Figure 3. Results of Sensitivity Analyses for the Association Between the Use of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) vs Dipeptidyl Peptidase 4 Inhibitors (DPP4i) and the Use of SGLT2i vs Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and the Risk of Overall Fractures.

HR indicates hazard ratio; NA, not applicable.

^aLaboratory test results were assessed within 3 years prior to the index date and the most recent value was included. Included laboratory variables comprised waist circumference, body mass index, fasting blood glucose, systolic blood pressure, diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, serum creatinine, estimated glomerular filtration rate, aspartate aminotransferase level, alanine aminotransferase level, gamma glutamyl transferase level, and smoking behavior, which presented varying missing rates of 27.9% to 60.5% for each variable.

^bAssessment period for baseline comorbidities was extended to include any time before the index date.